Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs

Biochemical Pharmacology

Volumn 68, Issue 11, 2004, Pages 2107-2116

  Phillips, Roger M ^a   Jaffar, Mohammed ^b   Maitland, Derek J ^a   Loadman, Paul M ^a   Shnyder, Steven D ^a   Steans, Gillian ^a   Cooper, Patricia A ^a   Race, Amanda ^a   Patterson, Adam V ^b   Stratford, Ian J ^b  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Bioreductive drugs; Hypoxia; Naphthoquinones; NQO1

Indexed keywords

1,4 NAPHTHOQUINONE DERIVATIVE; 2 ARIZIDINYL 5 HYDROXY 1,4 NAPHTHOQUINONE; 2 ARIZIDINYL 6 HYDROXYMETHYL 1,4 NAPHTHQUINONE; 2,3 BIS(ARIZIDINYL) 5 HYDROXY 1,4 NAPHTHOQUINONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; DRUG SOLUBILITY; EVALUATION; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; METABOLISM; MOUSE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; SUBSTITUTION REACTION; XENOGRAFT;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; AZIRIDINES; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; FEMALE; HUMANS; INDOLEQUINONES; MICE; NAD(P)H DEHYDROGENASE (QUINONE); NAPHTHOQUINONES; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 7444258436     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.08.007     Document Type: Article

References (38)

1. H.R. Hendriks, P.E. Pizao, D.P. Berger, K.L. Kooistra, M.C. Bibby, and E. Boven EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models Eur J Cancer 29A 1993 897 906
2. P. Workman Enzyme directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anti-cancer agents and quinone metabolising enzymes, particularly DT-diaphorase Oncol Res 6 1994 461 475
3. M.I. Walton, P.J. Smith, and P. Workman The role of NAD(P)H quinone reductase (EC 1.6.99.2 DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumour agent EO9 Cancer Commun 3 1991 199 206
4. S.M. Bailey, M.D. Wyatt, F. Friedlos, J.A. Hartley, R.J. Knox, and A.D. Lewis Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9 Br J Cancer 76 1997 1596 1603
5. N. Robertson, A. Haigh, G.E. Adams, and I.J. Stratford Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia Eur J Cancer 30A 1994 1013 1019
6. E. Smitkamp-Wilms, G.F. Peters, H.M. Pinedo, J. Van Arkotte, and G. Giaccone Chemosensitivity to the indolequinone EO9 is correlated with DT-diaphorase activity and gene expression Biochem Pharmacol 47 1994 1325 1332
7. J. Collard, A.M. Matthew, J.A. Double, and M.C. Bibby EO9: relationship between DT-diaphorase levels and response in vitro and in vivo Br J Cancer 71 1995 1199 1203
8. S.A. Fitzsimmons, P. Workman, M. Grever, K. Paull, R. Camalier, and A.D. Lewis Reductase enzyme expression across the National Cancer Institute tumour cell line panel: correlation with sensitivity to mitomycin C and EO9 J Natl Cancer Inst 88 1996 259 269
9. J.A. Plumb, and P. Workman Unusually marked hypoxic sensitisation to indoloquinone EO9 and Mitomycin C in a human colon cell line that lacks DT-diaphorase activity Int J Cancer 56 1994 134 139
10. J.A. Plumb, M. Gerritsen, and P. Workman DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9 Br J Cancer 70 1994 1136 1143
11. L.Y. Dirix, F. Tonnesen, J. Cassidy, R. Epelbaum, W.W. ten Bokkel Huinink, and N. Pavlidis EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group Eur J Cancer 32A 1996 2019 2022
12. N. Pavlidis, A.R. Hanauske, T. Gamucci, J. Smyth, M. Lehnert, and A. te Velde A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG) Ann Oncol 7 1996 529 531
13. T.A. Connors Bioreductive agents, hypoxic cells and therapy Eur J Cancer 32A 1996 1833 1834
14. R.M. Phillips, P.M. Loadman, and B.P. Cronin Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours Br J Cancer 77 1998 2112 2119
15. P. Vaupel, F. Kallinowski, and P. Okunieff Blood flow, oxygen and nutrient supply and metabolic microenvironment of human tumours: a review Cancer Res 49 1989 6449 6465
16. A.M. Malkinson, D. Siegel, G.L. Forrest, A.F. Gazdar, H.K. Oie, and D.C. Chan Elevated DT-diaphorase activity and messenger-RNA content in human non-small-cell lung-carcinoma-relationship to the response of lung tumor xenografts to mitomycin-C Cancer Res 52 1992 4752 4757
17. D. Siegel, W.A. Franklin, and D. Ross Immunohistochemical detection of NAD(P)H:Quinone oxidoreductase in human lung and lung tumours Clin Cancer Res 4 1999 2065 2070
18. J.H.M. Schellens, A.S.T. Planting, B.A.C. van Acker, W.J. Loos, M. de Boer-Dennert, and M.E.L. van der Burg Phase I and pharmacological study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9 J Natl Cancer Inst 86 1994 906 912
19. P.M. Loadman, M.C. Bibby, and R.M. Phillips Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9 Br J Pharmacol 137 2002 701 709
20. T.S. Lin, S.P. Xu, L.Y. Zhu, L.A. Cosby, and A.C. Sartorelli Synthesis of 2,3-diaziridinyl-1,4-naphthoquinone sulfonate derivatives as potential antineoplastic agents J Med Chem 32 1989 1467 1471
21. T.S. Lin, L.Y. Zhu, S.P. Xu, A.A. Divo, and A.C. Sartorelli Synthesis antimalarial activity of 2-aziridinyl- and 2,3-bis(aziridinyl)-1,4- naphthoquinonyl sulfonate and acylate derivatives J Med Chem 34 1991 1634 1639
22. Sartorelli AC, Lin TS. 2,3-Bis(azridinyl)-1,4-naphthoquinone sulphonate derivatives having antineoplastic activity. United States Patent. Patent number 4,806,531 (1989).
23. R.M. Phillips, M.A. Naylor, M. Jaffar, S.W. Doughty, S.A. Everett, and A.G. Breen Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure activity relationships J Med Chem 42 1999 4071 4080
24. G.A. Choudry, P.A. Hamilton-Stewart, J.A. Double, M.R.L. Krul, B. Naylor, and G.M. Flannigan A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase EC 1. 6. 99. 2) mediated therapy of bladder cancer based on the pharmacological properties of EO9 Br J Cancer 85 2001 1137 1146
25. R.D. Traver, T. Horikoshi, K.D. Dannenberg, T.H.W. Stadlbauer, P.V. Dannenberg, and D. Ross NAD(P)H:Quinone oxidoreductase gene expression in human colon carcinoma cells: characterisation of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity Cancer Res 52 1992 797 802
26. R.M. Phillips, P.B. Hulbert, M.C. Bibby, N.R. Sleigh, and J.A. Double In vitro activity of the novel indoloquinone EO9 and the influence of pH on cytotoxicity Br J Cancer 65 1992 359 364
27. R.L. Cowen, A.V. Patterson, B.A. Telfer, R.E. Airley, S. Hobbs, and R.M. Phillips Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts Mol Cancer Ther 2 2003 901 909
28. M. Jaffar, R.M. Phillips, K.J. Williams, I. Mrema, C. Cole, and N.S. Wind 3-Substituted-5-aziridinyl-1-methylindole-47-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro Biochem Pharmacol 66 2003 1199 1206
29. R.M. Phillips Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-47-dione] prop-β-en-α-ol (EO9) by human DT-diaphorase Biochem Pharmacol 52 1996 1711 1718
30. P. Workman, P. Twentyman, F. Balkwill, A. Balmain, D. Chaplin, and J.A. Double United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia Br J Cancer 77 1998 1 10
31. R.M. Phillips, A.M. Burger, P.M. Loadman, C.M. Jarret, D.J. Swaine, and H.H. Fiebig Predicting response to mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumour homogenates: implications for enzyme directed bioreductive drug development Cancer Res 60 2000 6384 6390
32. M.A. Naylor, M. Jaffar, J. Nolan, M.A. Stephens, S. Butler, and K.B. Patel 2-cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: structure-activity in vitro and efficacy in vivo J Med Chem 40 1997 2335 2346
33. H.D. Beall, S. Winski, E. Swann, A.R. Hudnott, A.S. Cotterill, and N. O'Sullivan Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity Med Chem 41 1998 4755 4766
34. E. Swann, P. Barraja, A.M. Oberlander, W.T. Gardipee, A.R. Hudnott, and H.D. Beall Indolequinone antitumor agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase. Part 2 J Med Chem 44 2001 3311 3319
35. E. Cadenas Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism Biochem Pharmacol 49 1995 127 140
36. P. Joseph, D.J. Long II, A.J.P. Klein-Szanto, and A.K. Jaiswal Role of NAD(P)H:quinone oxidoreductase 1 (DT-diaphorase) in protection against quinone toxicity Biochem Pharmacol 60 2000 207 214
37. S.L. Winski, E. Swann, R.H.J. Hargreaves, D.L. Dehn, J. Butler, and C.J. Moody Relationship between NAD(P)H:Quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumour quinines Biochem Pharmacol 61 2001 1509 1516
38. C. Giulivi, and E. Cadenas One and two electron reduction of 2-methyl-1,4-naphthoquinone bioreductive alkylating agents: kinetic studies, free radical production, thiol oxidation and DNA strand break formation Biochem J 301 1994 21 30